Polio vaccine attenuated vaccine strains. In 1958, the National Institutes of Health created a special committee on live polio vaccines. The various vaccines were carefully evaluated for their ability to induce immunity to polio, while retaining a low incidence of neuropathogenicity in monkeys. Large-scale clinical trials performed in the Soviet Union in late 1950s to early 1960s by Mikhail Chumakov and his colleagues demonstrated safety and high efficacy of the vaccine. Based on these results, the Sabin strains were chosen for worldwide distribution. Fifty-seven nucleotide substitutions distinguish the attenuated Sabin 1 strain from its virulent parent (the Mahoney serotype), two nucleotide substitutions
Sabin Vaccine Institute contribution to the field of vaccinology or related fields. The award is given in honor of the work of Albert B. Sabin. Past recipients of the award include Samuel L. Katz (2003), Joseph L. Melnick (1996), and Ruth S. Nussenzweig (2008). Sabin Vaccine Institute Sabin Vaccine Institute (Sabin), located in Washington, D.C., is a nonprofit (501(c)(3)) organization promoting global vaccine development, availability, and use. Through its work, Sabin hopes to reduce human suffering by preventing the spread of vaccine-preventable, communicable disease in humans through herd immunity, and also hopes to mitigate the poverty caused by these diseases. Founded in 1993